Jyoti Saini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jyoti Saini has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Atul Kumar Goyal
Department of Otolaryngology and Head & Neck Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
11 shared publications - Jaimanti Bakshi
Department of Otolaryngology and Head & Neck Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
10 shared publications - Maryada Sharma
Department of Otolaryngology and Head & Neck Surgery, Postgraduate Institute of Medical Education and Research, India
5 shared publications - Naresh Kumar Panda
Department of Ear, Nose, and Throat, Max Super Specialty Hospital, Mohali, India
5 shared publications - Ahmad K. Alnemare
Department of Otolaryngology, College of Medicine, Majmaah University, Al-Majmaah, Saudi Arabia
4 shared publications - Turki Bin Mahfoz
Department of Otolaryngology, Faculty of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
4 shared publications
Latest Publications
- 18 February 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (4) , 2203-2210
Head and Neck Cancer Burden Attributable to Tobacco and Alcohol in India: Evidence from NCRP 2020 and GLOBOCAN 2022
- 18 February 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (4) , 2203-2210
Head and Neck Cancer Burden Attributable to Tobacco and Alcohol in India: Evidence from NCRP 2020 and GLOBOCAN 2022
- 14 June 2025
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 25 (2) , 351-358
Quality of Life in Head and Neck Cancer: An EORTC-QLQ-H&N35 Based Assessment
Background Head and neck cancer is among the most prevalent cancers in India that impart significant physical and psychological morbidity in patients. The physical symptoms and psychological stress tend to impair the quality of life (QoL) of patients, which in turn affects the survival outcomes. Objective In the present study, we analyze the QoL of head and neck cancer patients using the EORTC-QLQ-H&N35 instrument so that an effective strategy to manage the QoL could be employed to improve treatment and survival outcomes. Methodology Total 205 head and neck cancer patients were included in the study and Hindi version of EORTC-QLQ-H&N35 was used to assessed the QoL. We analyze the QoL according to the sociodemographic factors and clinical determinants. QoL was analyzed according to various scales and subscales of EORTC-QLQ-H&N35. Results The mean global QoL score was 60.08 ± 19.06. QoL did not show any significant difference between the male (60.08 ± 19.06) and female (60.33 ± 19.31) gender. QoL was found to be significantly impaired at the advanced stages of the disease (56.02 ± 20.59). QoL was found to be significantly impaired in oral cancer patients (58.18 ± 19.70) compared to maxillary (66.66 ± 16.66) and larynx cancer (68.18 ± 13.41). In the context of the tumor site, QoL was most impaired in patients with tumors in the mandible region (38.88 ± 25.09). As per the addiction history among patients, the QoL does not show a significant difference among patients in terms of addiction history. Symptoms including nausea, vomiting, constipation and diarrhea are most commonly found to affect the QoL. All of the other factors including pain, less sexuality, mouth opening, dry mouth, sticky saliva were also found to affect the QoL. A higher use of painkillers (74.1%) and nutritional supplements (63.4%) was also observed among patients. Conclusion EORTC-QLQ-H&N35 is the most reliable instrument for assessing the QoL among head and neck cancer patients. The present study indicates that QoL was impaired significantly in head and neck cancer patients and needs to be addressed in treatment protocols.
- 14 June 2025
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 25 (2) , 351-358
Quality of Life in Head and Neck Cancer: An EORTC-QLQ-H&N35 Based Assessment
Background Head and neck cancer is among the most prevalent cancers in India that impart significant physical and psychological morbidity in patients. The physical symptoms and psychological stress tend to impair the quality of life (QoL) of patients, which in turn affects the survival outcomes. Objective In the present study, we analyze the QoL of head and neck cancer patients using the EORTC-QLQ-H&N35 instrument so that an effective strategy to manage the QoL could be employed to improve treatment and survival outcomes. Methodology Total 205 head and neck cancer patients were included in the study and Hindi version of EORTC-QLQ-H&N35 was used to assessed the QoL. We analyze the QoL according to the sociodemographic factors and clinical determinants. QoL was analyzed according to various scales and subscales of EORTC-QLQ-H&N35. Results The mean global QoL score was 60.08 ± 19.06. QoL did not show any significant difference between the male (60.08 ± 19.06) and female (60.33 ± 19.31) gender. QoL was found to be significantly impaired at the advanced stages of the disease (56.02 ± 20.59). QoL was found to be significantly impaired in oral cancer patients (58.18 ± 19.70) compared to maxillary (66.66 ± 16.66) and larynx cancer (68.18 ± 13.41). In the context of the tumor site, QoL was most impaired in patients with tumors in the mandible region (38.88 ± 25.09). As per the addiction history among patients, the QoL does not show a significant difference among patients in terms of addiction history. Symptoms including nausea, vomiting, constipation and diarrhea are most commonly found to affect the QoL. All of the other factors including pain, less sexuality, mouth opening, dry mouth, sticky saliva were also found to affect the QoL. A higher use of painkillers (74.1%) and nutritional supplements (63.4%) was also observed among patients. Conclusion EORTC-QLQ-H&N35 is the most reliable instrument for assessing the QoL among head and neck cancer patients. The present study indicates that QoL was impaired significantly in head and neck cancer patients and needs to be addressed in treatment protocols.
- 26 May 2025
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 25 (1) , 39-46
A Prospective Study on Analysis of Voice Quality in Head and Neck Cancer Patients
Background Voice is the critical component of communication, and impairment in voice quality tends to affect the overall health status of an individual. Voice quality tends to impair significantly in head and neck cancer patients because the tumors are usually present near the structures which were responsible for the production of voice. Objective The present study aimed to analyze the voice quality in head and neck cancer patients using three instruments including VHI, EORTC-QLQ-H&N35 and SSS. The objective of the study includes analysis of voice quality impairment in different domains including functional, physical, emotional impairment. We also aim to correlate the impartment in voice quality with the gender, cancer stage and site of the tumor. At last, our objective was to analyze the correlation of VHI with the EORTC-QLQ-H&N35 and SSS. Methods Totally, 205 adult head and neck cancer patients were recruited from the outpatient department. Sociodemographic and clinical data were collected using a predesigned proforma. Voice quality among patients was analyzed using the Hindi version of the VHI, EORTC-QLQ-H&N35 and SSS. Results The mean age of 205 patients was 52.79 ± 13.11 years, with a male predominance. Majority of patients presented with stage IV cancer. The most common cancer site was the oral cavity, including the tongue, buccal mucosa and alveolus. The functional and physical states of voice were found to be affected more than the emotional state among all patients. Voice quality was affected more in males compared to the female. Patients with the advanced stage of cancer have more impaired voices. Patients having cancer in the tongue, buccal mucosa, alveolus, larynx and palate tend to have more severely impaired voice quality. A strong correlation of VHI was observed with the SSS and EORTC-QLQ-HN35. Conclusion Voice quality was found to impair at a severe level in head and neck cancer patients. Further studies are required to validate the findings of this study to design treatment protocol that take voice quality of head and neck under consideration.
- 26 May 2025
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 25 (1) , 39-46
A Prospective Study on Analysis of Voice Quality in Head and Neck Cancer Patients
Background Voice is the critical component of communication, and impairment in voice quality tends to affect the overall health status of an individual. Voice quality tends to impair significantly in head and neck cancer patients because the tumors are usually present near the structures which were responsible for the production of voice. Objective The present study aimed to analyze the voice quality in head and neck cancer patients using three instruments including VHI, EORTC-QLQ-H&N35 and SSS. The objective of the study includes analysis of voice quality impairment in different domains including functional, physical, emotional impairment. We also aim to correlate the impartment in voice quality with the gender, cancer stage and site of the tumor. At last, our objective was to analyze the correlation of VHI with the EORTC-QLQ-H&N35 and SSS. Methods Totally, 205 adult head and neck cancer patients were recruited from the outpatient department. Sociodemographic and clinical data were collected using a predesigned proforma. Voice quality among patients was analyzed using the Hindi version of the VHI, EORTC-QLQ-H&N35 and SSS. Results The mean age of 205 patients was 52.79 ± 13.11 years, with a male predominance. Majority of patients presented with stage IV cancer. The most common cancer site was the oral cavity, including the tongue, buccal mucosa and alveolus. The functional and physical states of voice were found to be affected more than the emotional state among all patients. Voice quality was affected more in males compared to the female. Patients with the advanced stage of cancer have more impaired voices. Patients having cancer in the tongue, buccal mucosa, alveolus, larynx and palate tend to have more severely impaired voice quality. A strong correlation of VHI was observed with the SSS and EORTC-QLQ-HN35. Conclusion Voice quality was found to impair at a severe level in head and neck cancer patients. Further studies are required to validate the findings of this study to design treatment protocol that take voice quality of head and neck under consideration.
- 6 March 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (6) , 1590-1599
Prevalence, Incidence, and Mortality Trends of Head and Neck Cancers in India: A GLOBOCAN 2022 Statistics Analysis
Head and neck cancer is one of the most common cancers worldwide which exhibits a continuous rising trend of prevalence and incidence rates across the globe. Head and neck cancer is found to be more prevalent in developing nations like India where it is responsible for significant cancer-related mortality rate. We aim to analyze the prevalence, incidence, and mortality trends of head and neck cancers in India as per the latest Global Cancer Observatory (GLOBOCAN) 2022 estimates produced by the International Agency for Research on Cancer (IARC) and disseminated as Cancer Today on GLOBOCAN website. The GLOBOCAN 2022 database includes seven types of head and neck cancers, including the lip and oral cavity, hypopharynx, nasopharynx, oropharynx, salivary gland, larynx, and thyroid cancer. These categories are made according to the International Classification of Diseases Related Health Problems, 10th Revision (ICD-10) based on anatomical location of tumor. The data was extracted for the prevalence, incidence, and mortality rate. The incidence rate trend was analyzed for 15 years, from 2003 to 2017. The estimated rise in the incidence rate was predicted until 2050. The highest prevalence was reported for lip and oral cavity cancer which was 26.31, 17.07, and 6.4 for the 5 years, 3 years, and 1 year per 100,000 individuals respectively. The age-standardized rate (ASR) and crude incidence rate were highest for the lip and oral cavity cancers (9.91 and 10.22 respectively). The incidence rate of larynx and thyroid cancer remains stabilized over 15 years from year 2003 to 2017. The percent risk of rise of new cancer cases by the year 2050 is maximum for oropharynx cancer (103.9%). GLOBOCAN is one of most compressive global cancer databases which provides important insight regarding cancer across 185 countries. Head and neck cancer in India was found to impose a high prevalence, incidence, and mortality rate. Healthcare agencies need to derive an action plan to reduce the rising risk of head and neck cancer in India.
- 6 March 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (6) , 1590-1599
Prevalence, Incidence, and Mortality Trends of Head and Neck Cancers in India: A GLOBOCAN 2022 Statistics Analysis
Head and neck cancer is one of the most common cancers worldwide which exhibits a continuous rising trend of prevalence and incidence rates across the globe. Head and neck cancer is found to be more prevalent in developing nations like India where it is responsible for significant cancer-related mortality rate. We aim to analyze the prevalence, incidence, and mortality trends of head and neck cancers in India as per the latest Global Cancer Observatory (GLOBOCAN) 2022 estimates produced by the International Agency for Research on Cancer (IARC) and disseminated as Cancer Today on GLOBOCAN website. The GLOBOCAN 2022 database includes seven types of head and neck cancers, including the lip and oral cavity, hypopharynx, nasopharynx, oropharynx, salivary gland, larynx, and thyroid cancer. These categories are made according to the International Classification of Diseases Related Health Problems, 10th Revision (ICD-10) based on anatomical location of tumor. The data was extracted for the prevalence, incidence, and mortality rate. The incidence rate trend was analyzed for 15 years, from 2003 to 2017. The estimated rise in the incidence rate was predicted until 2050. The highest prevalence was reported for lip and oral cavity cancer which was 26.31, 17.07, and 6.4 for the 5 years, 3 years, and 1 year per 100,000 individuals respectively. The age-standardized rate (ASR) and crude incidence rate were highest for the lip and oral cavity cancers (9.91 and 10.22 respectively). The incidence rate of larynx and thyroid cancer remains stabilized over 15 years from year 2003 to 2017. The percent risk of rise of new cancer cases by the year 2050 is maximum for oropharynx cancer (103.9%). GLOBOCAN is one of most compressive global cancer databases which provides important insight regarding cancer across 185 countries. Head and neck cancer in India was found to impose a high prevalence, incidence, and mortality rate. Healthcare agencies need to derive an action plan to reduce the rising risk of head and neck cancer in India.
- 24 February 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (6) , 1468-1473
Classification of Numerical Score of Shame and Stigma Scale for Head and Neck Cancer into the Discrete Categories
The shame and stigma scale was developed to specifically analyze the shame and stigma in head and neck cancer patients. However, being a numerical rating scale, it gives a continuous number for each patient, which is difficult for clinicians to interpret. The present study aimed to classify the numerical rating score of the shame and stigma scale into the discrete categories of normal, mild, moderate, and severe. Data from 197 patients with head and neck cancer was obtained using the shame and stigma scale. The shame and stigma scale has a global score and four domains, with a high score representing a high rate of shame and stigma. The numerical score was used to create classification schemes to derive the optimum cutoff points for discrete categories. The variability of the optimal classification scheme was quantified using a bootstrap resampling procedure by repeating the patient sample a thousand times. The classification scheme with the highest F value in ANOVA was used to assign a cutoff to classify the numerical score into normal, mild, moderate, and severe categories. Seven classification schemes were created for global score, appearance domain and stigma domain. Five classification schemes were created for the regret domain, and three classification schemes were created for the speech domain. The optimum cutoff values for global score were 0–10 (normal), 11–30 (mild), 31–50 (moderate) and 51–80 (severe) (F = 1044.105); cutoff values for appearance domain were 0–6 (normal), 7–14 (mild), 15–22 (moderate) and 23–32 (severe) (F = 1344.50); cutoff values for stigma domain were 0–2 (normal), 3–7 (mild), 8–12 (moderate) and 13–20 (severe) (F = 1590.94); cutoff values for regret domain were 0–2 (normal), 3–6 (mild), 7–10 (moderate) and 11–16 (severe) (F = 924.03); and cutoff values for speech domain were 0–2 (normal), 3–5 (mild), 6–8 (moderate) and 9–12 (severe) (F = 1008.38). The present study classifies the numerical rating score of the shame and stigma scale into discrete categories i.e. normal, mild, moderate, and severe by obtaining the optimum cutoff points as per maximum F value. Clinicians can use these cutoff values to classify shame and stigma numerical scores as normal, mild, moderate, and severe for easy interpretation.
- 24 February 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (6) , 1468-1473
Classification of Numerical Score of Shame and Stigma Scale for Head and Neck Cancer into the Discrete Categories
The shame and stigma scale was developed to specifically analyze the shame and stigma in head and neck cancer patients. However, being a numerical rating scale, it gives a continuous number for each patient, which is difficult for clinicians to interpret. The present study aimed to classify the numerical rating score of the shame and stigma scale into the discrete categories of normal, mild, moderate, and severe. Data from 197 patients with head and neck cancer was obtained using the shame and stigma scale. The shame and stigma scale has a global score and four domains, with a high score representing a high rate of shame and stigma. The numerical score was used to create classification schemes to derive the optimum cutoff points for discrete categories. The variability of the optimal classification scheme was quantified using a bootstrap resampling procedure by repeating the patient sample a thousand times. The classification scheme with the highest F value in ANOVA was used to assign a cutoff to classify the numerical score into normal, mild, moderate, and severe categories. Seven classification schemes were created for global score, appearance domain and stigma domain. Five classification schemes were created for the regret domain, and three classification schemes were created for the speech domain. The optimum cutoff values for global score were 0–10 (normal), 11–30 (mild), 31–50 (moderate) and 51–80 (severe) (F = 1044.105); cutoff values for appearance domain were 0–6 (normal), 7–14 (mild), 15–22 (moderate) and 23–32 (severe) (F = 1344.50); cutoff values for stigma domain were 0–2 (normal), 3–7 (mild), 8–12 (moderate) and 13–20 (severe) (F = 1590.94); cutoff values for regret domain were 0–2 (normal), 3–6 (mild), 7–10 (moderate) and 11–16 (severe) (F = 924.03); and cutoff values for speech domain were 0–2 (normal), 3–5 (mild), 6–8 (moderate) and 9–12 (severe) (F = 1008.38). The present study classifies the numerical rating score of the shame and stigma scale into discrete categories i.e. normal, mild, moderate, and severe by obtaining the optimum cutoff points as per maximum F value. Clinicians can use these cutoff values to classify shame and stigma numerical scores as normal, mild, moderate, and severe for easy interpretation.
- 16 January 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (5) , 937-953
Matrix Metalloproteinases (MMPs) as Novel Prognostic Biomarkers to Predict Disease Progression, Survival Duration, and Recurrence Rate in Oral Cancer Patients
Oral cancer is the most common subtype of head and neck cancer, occupying a large proportion of all cancer patients in India. Since it is a non-communicable disease, it does not spread from person to person. The root of oral cancer development lies in the risk factors responsible for the disease. Addiction to tobacco and alcohol are the primary risk factors, followed by genetic and environmental factors. The gold standard treatment option for oral cancer includes the surgical excision of the tumor following the flap reconstruction for functional rehabilitation. Apart from this, help of radiotherapy, chemotherapy, and immunotherapy could be taken depending upon the disease condition. When patients get affected with the disease and visit the hospital, the primary concern of patients involves the course of disease progression, survival duration after the treatment, and the chance of recurrence of the disease. Despite advancements in medical technology, it is still not possible to predict the progression of disease, survival duration, and recurrence rate in oral cancer. Matrix metalloproteinases (MMPs) are novel biomarkers belonging to the family of the proteinases and are known to be involved in the degradation of the extracellular matrix (ECM). MMPs could be good predictors of disease progression, survival duration, and recurrence rate as the molecular changes appear in the body before the physical changes. By predicting the disease progression, survival duration, and recurrence rate of patients, it will become easy to manage the disease and improve the quality of life of the patients. MMPs can facilitate the regular monitoring of patients for changes in the tumor microenvironment, which can help monitor metastasis. In this review, we highlighted the various types of MMPs and their role in oral cancer. We also aim to integrate all the MMP data into a single molecular pathway so that scattered data can be observed as a useful information tool for further research.
- 16 January 2025
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (5) , 937-953
Matrix Metalloproteinases (MMPs) as Novel Prognostic Biomarkers to Predict Disease Progression, Survival Duration, and Recurrence Rate in Oral Cancer Patients
Oral cancer is the most common subtype of head and neck cancer, occupying a large proportion of all cancer patients in India. Since it is a non-communicable disease, it does not spread from person to person. The root of oral cancer development lies in the risk factors responsible for the disease. Addiction to tobacco and alcohol are the primary risk factors, followed by genetic and environmental factors. The gold standard treatment option for oral cancer includes the surgical excision of the tumor following the flap reconstruction for functional rehabilitation. Apart from this, help of radiotherapy, chemotherapy, and immunotherapy could be taken depending upon the disease condition. When patients get affected with the disease and visit the hospital, the primary concern of patients involves the course of disease progression, survival duration after the treatment, and the chance of recurrence of the disease. Despite advancements in medical technology, it is still not possible to predict the progression of disease, survival duration, and recurrence rate in oral cancer. Matrix metalloproteinases (MMPs) are novel biomarkers belonging to the family of the proteinases and are known to be involved in the degradation of the extracellular matrix (ECM). MMPs could be good predictors of disease progression, survival duration, and recurrence rate as the molecular changes appear in the body before the physical changes. By predicting the disease progression, survival duration, and recurrence rate of patients, it will become easy to manage the disease and improve the quality of life of the patients. MMPs can facilitate the regular monitoring of patients for changes in the tumor microenvironment, which can help monitor metastasis. In this review, we highlighted the various types of MMPs and their role in oral cancer. We also aim to integrate all the MMP data into a single molecular pathway so that scattered data can be observed as a useful information tool for further research.
- 23 October 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (2) , 601-610
Diagnostic and Prognostic Accuracy of MMPs and TIMPs in Oral Cancer Patients on Enzyme-Linked Immunosorbent Assay (ELISA) as Compared to Immunohistochemistry (IHC)
Oral cancer is one of most common noncommunicable diseases that imposed significant burden on healthcare around the globe including India. Several molecular markers have been extensively researched for their potential as diagnostic and prognostic biomarkers for oral cancer. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) found to play a crucial role in cytoskeleton dynamics and thus tumor growth and metastasis. The present study aims to analyze the MMP (MMP-1, MMP-3, MMP-9, and MMP-13) and TIMP (TIMP-1 and TIMP-3) expression in the oral cancer patients as compared to healthy controls. We also aim to compare the diagnostic accuracy of MMPs and TIMPs on enzyme-linked immunosorbent assay (ELISA) with respect to the immunohistochemistry (IHC). A total of 15 oral cancer patients and 14 healthy controls were enrolled in this study. Blood sample from oral cancer patients and healthy controls was obtained to analyze the MMP and TIMP expression levels in serum sample using ELISA. Tumor tissue sample from patients for IHC analysis was obtained by biopsy under local anesthesia. Data were compared between ELISA and IHC for sensitivity and specificity analysis. The mean age of the patients was 47.07 ± 15.74 years with the highest incidence of disease found in male gender (86.7%). MMPs and TIMPs exhibited higher expression in oral cancer patients as compared to healthy controls and the difference was statistically significant in case of MMP-13. MMPs and TIMPs showed stronger expression at advanced stages of cancer on IHC with MMP-9 exhibiting the highest expression level. The highest sensitivity and specificity on ELISA with respect to IHC were exhibited by the MMP-3 followed by MMP-13, TIMP-1, TIMP-3, and MMP-1. MMP-3 and MMP-13 were found to be reliable in terms of diagnostic marker for oral cancer as they found to have the highest sensitivity and specificity on ELISA with respect to IHC. MMP-9 was found to be reliable as a prognostic marker as it expresses highest on IHC at advanced stages of oral cancer.
- 23 October 2024
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 16 (2) , 601-610
Diagnostic and Prognostic Accuracy of MMPs and TIMPs in Oral Cancer Patients on Enzyme-Linked Immunosorbent Assay (ELISA) as Compared to Immunohistochemistry (IHC)
Oral cancer is one of most common noncommunicable diseases that imposed significant burden on healthcare around the globe including India. Several molecular markers have been extensively researched for their potential as diagnostic and prognostic biomarkers for oral cancer. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) found to play a crucial role in cytoskeleton dynamics and thus tumor growth and metastasis. The present study aims to analyze the MMP (MMP-1, MMP-3, MMP-9, and MMP-13) and TIMP (TIMP-1 and TIMP-3) expression in the oral cancer patients as compared to healthy controls. We also aim to compare the diagnostic accuracy of MMPs and TIMPs on enzyme-linked immunosorbent assay (ELISA) with respect to the immunohistochemistry (IHC). A total of 15 oral cancer patients and 14 healthy controls were enrolled in this study. Blood sample from oral cancer patients and healthy controls was obtained to analyze the MMP and TIMP expression levels in serum sample using ELISA. Tumor tissue sample from patients for IHC analysis was obtained by biopsy under local anesthesia. Data were compared between ELISA and IHC for sensitivity and specificity analysis. The mean age of the patients was 47.07 ± 15.74 years with the highest incidence of disease found in male gender (86.7%). MMPs and TIMPs exhibited higher expression in oral cancer patients as compared to healthy controls and the difference was statistically significant in case of MMP-13. MMPs and TIMPs showed stronger expression at advanced stages of cancer on IHC with MMP-9 exhibiting the highest expression level. The highest sensitivity and specificity on ELISA with respect to IHC were exhibited by the MMP-3 followed by MMP-13, TIMP-1, TIMP-3, and MMP-1. MMP-3 and MMP-13 were found to be reliable in terms of diagnostic marker for oral cancer as they found to have the highest sensitivity and specificity on ELISA with respect to IHC. MMP-9 was found to be reliable as a prognostic marker as it expresses highest on IHC at advanced stages of oral cancer.
- 12 May 2023
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 23 (5) , 1079-1088
Serum Concentration of MMP-9 as a Predictive Biomarker for the Progression of Oral Cancer
Background Oral cancer is the most prominent cancer subtype among all head and neck cancers, the incidence and prevalence of which has been consistently increasing in past years around the globe. At advanced stages, oral cancer imparts significant mortality, morbidity, and mutilation among the patients, and therefore, diagnosis and treatment of the disease at early stages are considered the optimum strategy for the management of the disease. Since molecular changes appear earlier than physical symptoms, several molecular biomarkers are currently being investigated for their role in diagnosing and treating disease. MMP-9 belongs to the family of proteinases that are involved in cytoskeletal degradation, which is a crucial phase of cancer progression. Objective In the present study, we analyzed the serum concentration of MMP-9 in oral cancer patients and tried to establish MMP-9 as a predictive biomarker for the progression of oral cancer. We also correlated the clinical, sociodemographic and biochemical parameters with the serum concentration of MMP-9 in oral cancer patients. Methods Serum was extracted from the blood sample of 38 oral cancer patients and was analyzed for the concentration of MMP-9 using sandwiched ELISA. Predesigned proforma was used to capture the clinical, sociodemographic and biochemical parameters. Unpaired t-test was used to compare two means, one way ANOVA was used to compare more than two means and Pearson's correlation was used to correlate the variables. Results The mean concentration of MMP-9 in patients of oral cancer was 816.9 ± 236.1 ng/mL. The MMP-9 expression level was higher at advanced oral cancer stages than in the early stages. No significant difference in the MMP expression was found in terms of sociodemographic risk factor and tumor site. MMP-9 exhibit significant negative correlation with the HDL and significantly positive correlation with the PTI. Rest of the biochemical parameters does not exhibit significant correlation. Conclusion The present study suggests that serum concentration of MMP-9 can be a predictive biomarker for the progression of oral cancer, which needs to be validated by performing further longitudinal cross-sectional studies by taking ample sample size.
- 12 May 2023
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 23 (5) , 1079-1088
Serum Concentration of MMP-9 as a Predictive Biomarker for the Progression of Oral Cancer
Background Oral cancer is the most prominent cancer subtype among all head and neck cancers, the incidence and prevalence of which has been consistently increasing in past years around the globe. At advanced stages, oral cancer imparts significant mortality, morbidity, and mutilation among the patients, and therefore, diagnosis and treatment of the disease at early stages are considered the optimum strategy for the management of the disease. Since molecular changes appear earlier than physical symptoms, several molecular biomarkers are currently being investigated for their role in diagnosing and treating disease. MMP-9 belongs to the family of proteinases that are involved in cytoskeletal degradation, which is a crucial phase of cancer progression. Objective In the present study, we analyzed the serum concentration of MMP-9 in oral cancer patients and tried to establish MMP-9 as a predictive biomarker for the progression of oral cancer. We also correlated the clinical, sociodemographic and biochemical parameters with the serum concentration of MMP-9 in oral cancer patients. Methods Serum was extracted from the blood sample of 38 oral cancer patients and was analyzed for the concentration of MMP-9 using sandwiched ELISA. Predesigned proforma was used to capture the clinical, sociodemographic and biochemical parameters. Unpaired t-test was used to compare two means, one way ANOVA was used to compare more than two means and Pearson's correlation was used to correlate the variables. Results The mean concentration of MMP-9 in patients of oral cancer was 816.9 ± 236.1 ng/mL. The MMP-9 expression level was higher at advanced oral cancer stages than in the early stages. No significant difference in the MMP expression was found in terms of sociodemographic risk factor and tumor site. MMP-9 exhibit significant negative correlation with the HDL and significantly positive correlation with the PTI. Rest of the biochemical parameters does not exhibit significant correlation. Conclusion The present study suggests that serum concentration of MMP-9 can be a predictive biomarker for the progression of oral cancer, which needs to be validated by performing further longitudinal cross-sectional studies by taking ample sample size.
- 6 January 2021
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 21 (2) , 326-331
Quality of Life in Oral Cancer Patients Following Surgical Excision and Flap Reconstruction
Background Incidence of oral cancer have been increased aggressively in recent years, and many advanced surgical techniques have developed to facilitate the treatment of disease while preserving the patient’s quality of life (QoL). Subjects and Methods The present study aims toward the evaluation of patient’s satisfaction toward the current treatment procedure for oral cancer by assessing the QoL preoperatively and postoperatively. In the study period of four years, we had operated 150 patients with oral cancer (Stage III and IVa) by surgical excision and flap reconstruction, and QoL was assessed using the WHO-QoL BREF questionnaire. Results We found significant improvement after surgery in various aspects of QoL including the physical health, social health, psychological health and environmental health. Conclusions The present study is evidence of patient satisfaction toward the current treatment protocols of oral cancer. However, advanced surgical techniques that can enhance the rate of functional rehabilitation can have paramount importance in improving the patient’s QoL.
- 6 January 2021
- Published by Springer Nature in Journal of Maxillofacial and Oral Surgery
- Vol. 21 (2) , 326-331
Quality of Life in Oral Cancer Patients Following Surgical Excision and Flap Reconstruction
Background Incidence of oral cancer have been increased aggressively in recent years, and many advanced surgical techniques have developed to facilitate the treatment of disease while preserving the patient’s quality of life (QoL). Subjects and Methods The present study aims toward the evaluation of patient’s satisfaction toward the current treatment procedure for oral cancer by assessing the QoL preoperatively and postoperatively. In the study period of four years, we had operated 150 patients with oral cancer (Stage III and IVa) by surgical excision and flap reconstruction, and QoL was assessed using the WHO-QoL BREF questionnaire. Results We found significant improvement after surgery in various aspects of QoL including the physical health, social health, psychological health and environmental health. Conclusions The present study is evidence of patient satisfaction toward the current treatment protocols of oral cancer. However, advanced surgical techniques that can enhance the rate of functional rehabilitation can have paramount importance in improving the patient’s QoL.